Biotech Security for Research IP & Clinical Data
We help biotech and life sciences companies build security programs that protect research IP, secure clinical trial data, meet FDA cybersecurity requirements, and support investor confidence.
Why Biotech Security Matters
Biotech companies face a unique security landscape where intellectual property is your most valuable asset and regulatory scrutiny is constant.
FDA Cybersecurity Requirements
FDA guidance increasingly focuses on cybersecurity controls for medical devices and clinical data systems. The FDA expects companies to demonstrate secure design practices, threat modeling, vulnerability management, and incident response capabilities. Missing these controls puts your approval timeline at risk.
Clinical Trial Data Protection
Clinical trials generate highly sensitive data subject to both HIPAA (if you handle PHI) and FDA regulations. Data integrity failures, unauthorized access, or breaches can invalidate trial results, delay submissions, and trigger regulatory investigations. Your data systems need to prove data integrity and access controls.
Research IP Theft
Biotech companies are targets for IP theft - both from external competitors and internal threats. Your research databases, lab notebooks, formulations, and clinical data represent years of R&D investment and significant valuation drivers. Without proper access controls and monitoring, compromised IP can mean lost competitive advantage or leaked trials.
Research Data Governance
Growth-stage biotech companies often have fragmented data systems - lab information management systems (LIMS), electronic lab notebooks (ELNs), clinical data systems, and research collaboration tools. Securing and governing this ecosystem while enabling researcher productivity requires thoughtful architecture.
Investor and Partner Due Diligence
VCs, strategic partners, and potential acquirers now conduct detailed security assessments. They're looking for evidence that you can protect sensitive data, maintain data integrity, and meet regulatory requirements. Security maturity is increasingly a deal factor.
When to Engage Security Leadership
You don't need perfect security to advance your research, but you do need a plan. Here are signs you should engage security leadership now:
Regulatory & Compliance Signals:
- FDA asking about cybersecurity controls in pre-submission meetings
- Preparing for FDA submission or 510(k) approval
- Handling clinical trial data without documented security controls
- Need to demonstrate HIPAA compliance for patient data
- Customer or partner security assessments focused on data integrity
Business & Growth Signals:
- Planning a Series A/B fundraise with investor due diligence
- M&A activity or acquisition discussions requiring security validation
- Need to demonstrate security posture to strategic partners
- Clinical trials requiring patient safety and data integrity commitments
- Expanding to work with healthcare systems or CROs requiring security evidence
Operational Signals:
- Research data spread across unsecured systems with unclear access controls
- No one responsible for research data governance or security
- Difficulty answering "how do we prevent unauthorized access to proprietary research?"
- Concern about insider threats or IP theft
- Recent security incident raising internal concerns
Technology Signals:
- No encryption for research data at rest or in transit
- Cloud infrastructure never assessed for security or compliance
- Lab systems (LIMS, ELNs) never evaluated for security controls
- Unable to track who accessed sensitive research and when
- Backup and disaster recovery plans don't address research data
How We Help Biotech Companies
Our Approach for Biotech Security
We work with biotech companies through a phased approach focused on protecting your most valuable assets - research IP and clinical data.
FDA Cybersecurity Compliance
We help you understand FDA expectations and build the controls they want to see: threat modeling, vulnerability management, secure development practices, and incident response. We make FDA submissions stronger by demonstrating mature cybersecurity practices.
Research IP Protection Strategy
We help you classify research data by sensitivity, implement appropriate access controls (who can access what), set up monitoring for suspicious access patterns, and design your security architecture to prevent both external and internal IP theft.
Clinical Trial Data Security
Clinical data systems need to prove data integrity - you need to show that only authorized modifications occur and that you can detect tampering. We design and implement the controls that satisfy both FDA and HIPAA requirements.
Research Data Governance
We help you create a data governance program that works with your research teams, not against them. This includes designing secure LIMS/ELN implementations, managing research collaboration tools securely, and creating processes that researchers actually follow.
SOC 2 and HIPAA Compliance
If you're handling patient data or working with healthcare partners, SOC 2 Type II and HIPAA compliance become necessary. We guide you through both frameworks with a focus on the biotech-specific requirements.
Common Questions About Biotech Security
What are FDA's cybersecurity requirements for biotech companies?
FDA guidance requires companies to implement secure design practices, threat modeling, vulnerability management, and incident response for medical devices and clinical data systems. The FDA expects to see evidence that you understand potential cybersecurity threats, have designed controls to mitigate them, and can detect and respond to incidents. This applies to device software, clinical trial systems, and manufacturing systems.
How do we protect proprietary research from IP theft?
Effective research IP protection requires multiple layers: (1) identifying and classifying sensitive research data, (2) implementing access controls so only authorized researchers access what they need, (3) encrypting sensitive data at rest and in transit, (4) monitoring access and detecting unusual patterns, (5) secure data disposal, and (6) incident response plans. The key is balancing security with researcher productivity.
Are clinical trials subject to HIPAA or just FDA regulations?
If your clinical trials collect, store, or transmit protected health information (PHI) - like patient medical records - you must comply with HIPAA as a covered entity or business associate. Even if you're not directly treating patients, if you're working with healthcare providers or handling patient data, HIPAA applies. You'll need both HIPAA compliance and FDA's cybersecurity requirements for clinical trial data.
What should be our biotech security priorities?
Prioritize based on your stage and risks: early-stage should focus on research data classification and access controls, growth-stage companies should implement FDA-compliant security architecture and HIPAA/SOC 2 if handling healthcare data, and pre-submission companies should ensure FDA expectations are documented. Most biotech companies should prioritize research IP protection, clinical data integrity, and FDA readiness in that order.
Have more questions?
View all frequently asked questionsRelated Biotech & Healthcare Services
Ready to Strengthen Your Biotech Security?
Let's discuss your research IP protection, clinical data security, and FDA compliance needs.